NCT04324268View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

March 23, 2020

Primary Completion Date

February 10, 2021

Study Completion Date

February 10, 2021

Conditions
Study Conducted in Healthy Volunteers
Interventions
DRUG

lirentelimab (AK002)

Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.

OTHER

Placebo

Placebo

Trial Locations (1)

32132

Allakos Investigational Site, Edgewater

Sponsors

Lead Sponsor

Allakos Inc.
All Listed Sponsors
lead

Allakos Inc.

INDUSTRY

NCT04324268 - A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers | Biotech Hunter | Biotech Hunter